Advanced search
Publication Cover
Pharmaceutical Biology Volume 55, 2017 - Issue 1
Submit an article Journal homepage
2,274
Views
22
CrossRef citations to date
0
Altmetric
Research Article

Sorbus alnifolia protects dopaminergic neurodegeneration in Caenorhabditis elegans

Se-Myeong CheonCollege of Pharmacy, Woosuk University, Jeonbuk, Republic of Korea;
,
Insoo JangDepartment of Korean Internal Medicine, Woosuk University, Jeonbuk, Republic of Korea;
,
Myon-Hee LeeDepartment of Medicine, Brody School of Medicine at East, Carolina University, Greenville, NC, USA
,
Dae Keun KimCollege of Pharmacy, Woosuk University, Jeonbuk, Republic of Korea;
,
Hoon JeonCollege of Pharmacy, Woosuk University, Jeonbuk, Republic of Korea;
&
Dong Seok ChaCollege of Pharmacy, Woosuk University, Jeonbuk, Republic of Korea; Correspondence[email protected]
Pages 481-486 | Received 14 Apr 2016, Accepted 18 Oct 2016, Published online: 09 Dec 2016

References

  • Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, et al. 2006. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet. 38:515–517.
  • Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM. 2001. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson’s disease. Prog Neurobiol. 65:135–172.
  • Braungart E, Gerlach M, Riederer P, Baumeister R, Hoener MC. 2004. Caenorhabditis elegans MPP+ model of Parkinson’s disease for high-throughput drug screenings. Neurodegener Dis. 1:175–183.
  • Brenner S. 1974. The genetics of Caenorhabditis elegans. Genetics. 77:71–94.
  • Butler B, Saha K, Rana T, Becker JP, Sambo D, Davari P, Goodwin JS, Khoshbouei H. 2015 . Dopamine transporter activity is modulated by α-synuclein. J Biol Chem. 290:29542–29554.
  • Cao S, Gelwix CC, Caldwell KA, Caldwell GA. 2005. Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J Neurosci. 25:3801–3812.
  • Dawson TM, Dawson VL. 2002. Neuroprotective and neurorestorative strategies for Parkinson’s disease. Nat Neurosci. 5(Suppl):1058–1061.
  • Dias V, Junn E, Mouradian MM. 2013. The role of oxidative stress in Parkinson’s disease. J Parkinsons Dis. 3:461–491.
  • Farrer M, Kachergus J, Forno L, Lincoln S, Wang DS, Hulihan M, Maraganore D, Gwinn-Hardy K, Wszolek Z, Dickson D, et al. 2004. Comparison of kindreds with Parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol. 55:174–179.
  • Gomez Arevalo G, Jorge R, Garcia S, Scipioni O, Gershanik O. 1997. Clinical and pharmacological differences in early- versus late-onset Parkinson’s disease. Mov Disord. 12:277–284.
  • Jadiya P, Khan A, Sammi SR, Kaur S, Mir SS, Nazir A. 2011. Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson’s disease. Biochem Biophys Res Commun. 413:605–610.
  • Katzen HL, Levin BE, Llabre ML. 1998. Age of disease onset influences cognition in Parkinson's disease. J Int Neuropsychol Soc. 4:285–290.
  • Kook YH, Ka M, Um M. 2011 . Neuroprotective cytokines repress PUMA induction in the 1-methyl-4-phenylpyridinium (MPP(+)) model of Parkinson’s disease. Biochem Biophys Res Commun. 411:370–374.
  • Langston JW, Ballard P, Tetrud JW, Irwin I. 1983. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:979–980.
  • Levy G. 2007. The relationship of Parkinson disease with aging. Arch Neurol. 64:1242–1246.
  • Li X, Chen W, Zhang L, Liu WB, Fei Z. 2013 . Inhibition of store-operated calcium entry attenuates MPP(+)-induced oxidative stress via preservation of mitochondrial function in PC12 cells: involvement of Homer1a. PLoS One. 8:e83638. doi: 10.1371/journal.pone.0083638.
  • Liou AK, Zhou Z, Pei W, Lim TM, Yin XM, Chen J. 2005. BimEL up-regulation potentiates AIF translocation and cell death in response to MPTP. FASEB J. 19:1350–1352.
  • Parker WD Jr, Parks JK. 2005. Mitochondrial ND5 mutations in idiopathic Parkinson’s disease. Biochem Biophys Res Commun. 326:667–669.
  • Sawin ER, Ranganathan R, Horvitz HR. 2000. C. elegans locomotory rate is modulated by the environment through a dopaminergic pathway and by experience through a serotonergic pathway. Neuron. 26:619–631.
  • Schmidt E, Seifert M, Baumeister R. 2007. Caenorhabditis elegans as a model system for Parkinson’s disease. Neurodegener Dis. 4:199–217.
  • Schmidt N, Ferger B. 2001. Neuroprotective effects of (+/−)-kavain in the MPTP mouse model of Parkinson’s disease. Synapse. 40:47–54.
  • Schober A. 2004. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 318:215–224.
  • Takashima A, Koike T. 1985. Relationship between dopamine content and its secretion in PC12 cells as a function of cell growth. Biochim Biophys Acta. 847:101–107.
  • Trimmer PA, Bennett JP Jr. 2009. The cybrid model of sporadic Parkinson's disease. Exp Neurol. 218:320–325.
  • van Ham TJ, Thijssen KL, Breitling R, Hofstra RM, Plasterk RH, Nollen EA. 2008. C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet. 4:e1000027. doi: 10.1371/journal.pgen.1000027.
  • Yankner BA, Lu T, Loerch P. 2008. The aging brain. Annu Rev Pathol. 3:41–66.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.